{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:09:56Z","timestamp":1790104196195,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Verastem, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00280-016-3010-1","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T06:28:07Z","timestamp":1459319287000},"page":"997-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"77","author":[{"given":"Toshio","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Horobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou","family":"Vaickus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Padval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"issue":"11 Pt 1","key":"3010_CR1","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-06-0456","volume":"12","author":"PM Siesser","year":"2006","unstructured":"Siesser PM, Hanks SK (2006) The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12(11 Pt 1):3233\u20133237","journal-title":"Clin Cancer Res"},{"key":"3010_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1517\/14728220903460340","volume":"14","author":"J Schwock","year":"2010","unstructured":"Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14:77\u201394","journal-title":"Expert Opin Ther Targets"},{"key":"3010_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/13543784.2010.489548","volume":"19","author":"A Schultze","year":"2010","unstructured":"Schultze A, Fiedler W (2010) Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 19:777\u2013788","journal-title":"Expert Opin Investig Drugs"},{"key":"3010_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbamcr.2004.04.008","volume":"1692","author":"DD Schlaepfer","year":"2004","unstructured":"Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77\u2013102","journal-title":"Biochim Biophys Acta"},{"key":"3010_CR5","first-page":"973","volume":"22","author":"H Hao","year":"2009","unstructured":"Hao H, Naomoto Y, Bao X et al (2009) Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep 22:973\u2013979","journal-title":"Oncol Rep"},{"key":"3010_CR6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2007.08.002","volume":"18","author":"RW Tilghman","year":"2008","unstructured":"Tilghman RW, Parsons JT (2008) Focal adhesion kinase as a regulator of cell tension in the progression of cancer. Semin Cancer Biol 18:45\u201352","journal-title":"Semin Cancer Biol"},{"issue":"19","key":"3010_CR7","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"MF Clarke","year":"2006","unstructured":"Clarke MF, Dick JE, Dirks PB et al (2006) Cancer stem cells\u2014perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66(19):9339\u20139344","journal-title":"Cancer Res"},{"issue":"8","key":"3010_CR8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/2159-8290.CD-11-0239","volume":"2","author":"T Shibue","year":"2012","unstructured":"Shibue T, Brooks MW, Fatih Inan M et al (2012) The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov 2(8):706\u2013721","journal-title":"Cancer Discov"},{"issue":"5","key":"3010_CR9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Shapiro GI et al (2015) A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs 33(5):1100\u20131107","journal-title":"Invest New Drugs"},{"key":"3010_CR10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","volume":"30","author":"JR Infante","year":"2012","unstructured":"Infante JR, Camidge DR, Mileshkin LR et al (2012) Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30:1527\u20131533","journal-title":"J Clin Oncol"},{"key":"3010_CR11","doi-asserted-by":"crossref","unstructured":"Zer A, Verheijen RB, De Vos F et al (2015) A phase I study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors. J Clin Oncol 33 (suppl; abstr 2541)","DOI":"10.1200\/jco.2015.33.15_suppl.2541"},{"key":"3010_CR12","doi-asserted-by":"crossref","unstructured":"Doi T, Lin CC, Ohtsu A et al (2014) A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors. Eur J Cancer 50 (suppl 6; abstr 213)","DOI":"10.1016\/S0959-8049(14)70339-9"},{"key":"3010_CR13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/bbrc.2002.6400","volume":"291","author":"K Jemnitz","year":"2002","unstructured":"Jemnitz K, Lengyel G, Vereczkey L (2002) In vitro induction of bilirubin conjugation in primary rat hepatocyte culture. Biochem Biophys Res Commun 291:29\u201333","journal-title":"Biochem Biophys Res Commun"},{"key":"3010_CR14","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","volume":"98","author":"SD Zucker","year":"2001","unstructured":"Zucker SD, Qin X, Rouster SD et al (2001) Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671\u201312676","journal-title":"Proc Natl Acad Sci USA"},{"key":"3010_CR15","doi-asserted-by":"crossref","unstructured":"Soria JC, Gan HK, Arkenau HT et al (2012) Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors. J Clin Oncol 30 (Suppl) Abst. 3000","DOI":"10.1200\/jco.2012.30.15_suppl.3000"},{"key":"3010_CR16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-12-0388","volume":"3","author":"G Konstantinidou","year":"2013","unstructured":"Konstantinidou G, Ramadori G, Torti F et al (2013) RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov 3:444\u2013457","journal-title":"Cancer Discov"},{"key":"3010_CR17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels A, Lund T, Serrels B et al (2015) Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell 163:160\u2013173","journal-title":"Cell"},{"key":"3010_CR18","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos PI, Xiao GH, Gallagher R et al (2006) Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25:5960\u20135968","journal-title":"Oncogene"},{"key":"3010_CR19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen C, Opitz I, Kurtz S et al (2009) Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer 64:140\u2013147","journal-title":"Lung Cancer"},{"key":"3010_CR20","first-page":"237","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM et al (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 6:237\u2013268","journal-title":"Sci Transl Med"},{"issue":"Suppl 6","key":"3010_CR21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0959-8049(12)72407-3","volume":"48","author":"JC Soria","year":"2012","unstructured":"Soria JC, Plummer R, Ranson M et al (2012) Loss of the tumor suppressor Merlin as a potential predictive biomarker of clinical activity for the oral, focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with recurrent mesothelioma. Eur J Cancer 48(Suppl 6):188 (Abst. 610)","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3010-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T23:15:05Z","timestamp":1600384505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3010"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3010-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}